Diego Muñoz-Torrero

Dr. Diego Muñoz-Torrero

Laboratory of Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Diego Muñoz-TorreroDiego Muñoz-Torrero
Diego Muñoz-Torrero
The therapeutic arsenal for the treatment of Alzheimers disease (AD) remains confined to a group of four inhibitors of AChE and one NMDA receptor antagonist, which are used to provide a relief of the very late symptoms of the dementia, i.e. the cognitive and functional decline. In line with the growing body of evidence of the pivotal role of the β-amyloid peptide (Aβ) in the pathogenesis of AD, alternative classes of drugs targeting mainly the formation or the aggregation of Aβ are actively pursued by the pharmaceutical industry, as they could positively modify the course of AD, stopping or slowing down disease progression. While the first amyloid-directed disease-modifying drugs go ahead with their clinical development and could reach the market as soon as 2009, mounting preclinical and clinical evidences is pointing towards a disease-modifying role also for currently marketed anti-Alzheimer AChE inhibitors (AChEIs), particularly for donepezil. In this review, the neuroprotective effects exhibited by currently commercialized AChEIs will be briefly discussed, together with the secondary mechanisms through which they could exert such effects. This review will focus also on particular classes of AChEIs, namely dual binding site AChEIs, which are being purposely designed to target Aβ aggregation and / or other biological targets that contribute to AD pathogenesis, thus constituting very promising diseasemodifying anti-Alzheimer drug candidates.

1 June 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PCPelayo Camps
Pelayo Camps
XFXavier Formosa
Xavier Formosa
CGCarles Galdeano
Carles Galdeano
TGTània Gómez
Tània Gómez
Diego Muñoz-TorreroDiego Muñoz-Torrero
Diego Muñoz-Torrero
FLF. Javier Luque
F. Javier Luque

1 November 2000 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PCPelayo Camps
Pelayo Camps
RARachid El Achab
Rachid El Achab
JMJordi Morral
Jordi Morral
Diego Muñoz-TorreroDiego Muñoz-Torrero
Diego Muñoz-Torrero
ABAlbert Badia
Albert Badia
FLF. Javier Luque
F. Javier Luque

7 August 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PCPelayo Camps
Pelayo Camps
XFXavier Formosa
Xavier Formosa
CGCarles Galdeano
Carles Galdeano
Diego Muñoz-TorreroDiego Muñoz-Torrero
Diego Muñoz-Torrero
LRLorena Ramírez
Lorena Ramírez
FLF. Javier Luque
F. Javier Luque

10 March 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
EVElisabet Viayna
Elisabet Viayna
ISIrene Sola
Irene Sola
MBManuela Bartolini
Manuela Bartolini
ASAngela De Simone
Angela De Simone
CTCheril Tapia-Rojas
Cheril Tapia-Rojas
Diego Muñoz-TorreroDiego Muñoz-Torrero
Diego Muñoz-Torrero
We have synthesized a family of rhein–huprine hybrids to hit several key targets for Alzheimer’s disease. Biological screening performed in vitro and in Escherichia coli cells has shown that these hybrids exhibit potent inhibitory activities against human acetylcholinesterase, butyrylcholinesterase, and BACE-1, dual Aβ42 and tau antiaggregating activity, and brain permeability. Ex vivo studies with the leads (+)- and (−)-7e in brain slices of C57bl6 mice have revealed that they efficiently protect against the Aβ-induced synaptic dysfunction, preventing the loss of synaptic proteins and/or have a positive effect on the induction of long-term potentiation. In vivo studies in APP-PS1 transgenic mice treated ip for 4 weeks with (+)- and (−)-7e have shown a central soluble Aβ lowering effect, accompanied by an increase in the levels of mature amyloid precursor protein (APP). Thus, (+)- and (−)-7e emerge as very promising disease-modifying anti-Alzheimer drug candidates.

6 February 2002 in Biochemistry
Verified
Journal Article
Closed access
HDH. Dvir
H. Dvir
DWDawn Wong
Dawn Wong
MHM. Harel
M. Harel
XBXavier Barril
Xavier Barril
MOM. Orozco
M. Orozco
Joel SussmanJoel Sussman
Joel Sussman